Microbot Med Inc Financials

MBOT

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Microbot Med Inc (MBOT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Microbot Med Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.77x

For every $1 of reported earnings, Microbot Med Inc generates $0.77 in operating cash flow (-$8.8M OCF vs -$11.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$11.5M

YoY-18.3%

Microbot Med Inc's EBITDA was -$11.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.3% from the prior year.

Free Cash Flow

-$8.9M

YoY-3.3%

Microbot Med Inc generated -$8.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 3.3% from the prior year.

Net Income

-$11.4M

YoY-6.5%

Microbot Med Inc reported -$11.4M in net income in fiscal year 2024. This represents a decrease of 6.5% from the prior year.

EPS (Diluted)

$-0.73

YoY+30.5%

Microbot Med Inc earned $-0.73 per diluted share (EPS) in fiscal year 2024. This represents an increase of 30.5% from the prior year.

Cash & Debt

$3.1M

YoY+26.2%

5Y CAGR-35.9%

10Y CAGR+14.7%

Microbot Med Inc held $3.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

19M

YoY+65.7%

5Y CAGR+22.0%

Microbot Med Inc had 19M shares outstanding in fiscal year 2024. This represents an increase of 65.7% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$6.6M

YoY+15.8%

5Y CAGR+16.8%

10Y CAGR+23.0%

Microbot Med Inc invested $6.6M in research and development in fiscal year 2024. This represents an increase of 15.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$25K

YoY-24.2%

5Y CAGR-35.0%

10Y CAGR+8.1%

Microbot Med Inc invested $25K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 24.2% from the prior year.

MBOT Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$6.6M+15.8%	$5.7M-26.0%	$7.7M+25.7%	$6.2M+81.2%	$3.4M+11.4%	$3.0M
SG&A Expenses	$5.0M+20.9%	$4.1M-25.5%	$5.5M+6.6%	$5.2M-8.6%	$5.7M+35.8%	$4.2M
Operating Income	-$11.6M-18.0%	-$9.9M+25.8%	-$13.3M-16.9%	-$11.4M-25.0%	-$9.1M-25.5%	-$7.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	$0	$0
Net Income	-$11.4M-6.5%	-$10.7M+18.4%	-$13.2M-16.4%	-$11.3M-23.4%	-$9.2M-26.5%	-$7.2M
EPS (Diluted)	$-0.73+30.5%	$-1.05+42.0%	$-1.81	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.2M-43.2%	$2.1M	N/A	$1.6M	N/A	$2.0M	N/A	$1.4M
SG&A Expenses	$2.7M+116.9%	$1.2M	N/A	$932K	N/A	$1.5M	N/A	$1.2M
Operating Income	-$3.9M-17.0%	-$3.3M	N/A	-$2.5M	N/A	-$3.5M	N/A	-$2.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.6M-11.3%	-$3.2M	N/A	-$2.4M	N/A	-$3.5M	N/A	-$2.6M
EPS (Diluted)	$-0.07	$-0.20	N/A	$-0.21	N/A	$-0.49	N/A	N/A

MBOT Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$6.0M-27.6%	$8.3M-12.7%	$9.5M-43.1%	$16.8M-36.2%	$26.3M-29.2%	$37.1M
Current Assets	$5.8M-26.5%	$7.9M-10.1%	$8.8M-44.5%	$15.9M-37.1%	$25.3M-29.7%	$35.9M
Cash & Equivalents	$3.1M+26.2%	$2.5M+1.1%	$2.4M-81.9%	$13.5M-31.3%	$19.6M-31.7%	$28.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-34.6%	$3.8M+70.2%	$2.2M-5.8%	$2.4M+21.1%	$2.0M-64.7%	$5.6M
Current Liabilities	$2.5M-35.0%	$3.8M+83.0%	$2.1M+4.3%	$2.0M+47.5%	$1.3M-72.1%	$4.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.5M-21.6%	$4.5M-38.2%	$7.3M-49.3%	$14.4M-40.8%	$24.3M-22.9%	$31.5M
Retained Earnings	-$90.9M-14.4%	-$79.5M-15.6%	-$68.8M-23.7%	-$55.6M-25.5%	-$44.3M-26.1%	-$35.1M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Total Assets	$81.8M+1255.7%	$6.0M-27.6%	$8.3M-6.3%	$8.9M-6.8%	$9.5M+28.7%	$7.4M-55.8%	$16.8M-14.9%	$19.7M
Current Assets	$80.8M+1288.3%	$5.8M-26.5%	$7.9M-5.8%	$8.4M-4.6%	$8.8M+33.5%	$6.6M-58.4%	$15.9M-15.5%	$18.8M
Cash & Equivalents	$6.7M+115.3%	$3.1M+26.2%	$2.5M+84.9%	$1.3M-45.3%	$2.4M-43.6%	$4.3M-67.9%	$13.5M+0.5%	$13.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.5M+41.4%	$2.5M-34.6%	$3.8M+150.1%	$1.5M-31.9%	$2.2M+19.8%	$1.9M-21.4%	$2.4M+30.3%	$1.8M
Current Liabilities	$2.9M+19.3%	$2.5M-35.0%	$3.8M+153.9%	$1.5M-27.9%	$2.1M+25.4%	$1.6M-16.8%	$2.0M+42.2%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$78.2M+2116.0%	$3.5M-21.6%	$4.5M-38.8%	$7.4M+0.9%	$7.3M+31.7%	$5.5M-61.5%	$14.4M-19.5%	$17.9M
Retained Earnings	-$100.6M-10.6%	-$90.9M-14.4%	-$79.5M-4.1%	-$76.3M-11.0%	-$68.8M-4.6%	-$65.8M-18.3%	-$55.6M-7.5%	-$51.7M

MBOT Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$8.8M-3.4%	-$8.5M+26.1%	-$11.5M-23.5%	-$9.4M-29.0%	-$7.3M-12.4%	-$6.5M
Capital Expenditures	$25K-24.2%	$33K-60.7%	$84K+21.7%	$69K-24.2%	$91K-57.9%	$216K
Free Cash Flow	-$8.9M-3.3%	-$8.6M+26.4%	-$11.6M-23.5%	-$9.4M-28.3%	-$7.3M-10.1%	-$6.7M
Investing Cash Flow	$1.5M-22.1%	$2.0M+151.4%	-$3.8M-219.9%	$3.2M+215.6%	-$2.8M-12.8%	-$2.5M
Financing Cash Flow	$7.9M+21.0%	$6.6M+51.7%	$4.3M	N/A	-$3.4M-109.2%	$36.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Operating Cash Flow	-$3.8M-127.1%	-$1.7M+7.1%	-$1.8M-10.0%	-$1.7M+32.8%	-$2.5M+16.6%	-$3.0M-2.4%	-$2.9M-32.7%	-$2.2M
Capital Expenditures	$13K+85.7%	$7K+240.0%	-$5K-117.9%	$28K+2700.0%	$1K-80.0%	$5K-88.6%	$44K+214.3%	$14K
Free Cash Flow	-$3.9M-127.0%	-$1.7M+7.0%	-$1.8M-8.5%	-$1.7M+31.7%	-$2.5M+16.8%	-$3.0M-1.0%	-$2.9M-33.8%	-$2.2M
Investing Cash Flow	-$44.7M-3090.8%	$1.5M-49.4%	$3.0M+215.0%	-$2.6M+31.5%	-$3.8M-74960.0%	-$5K-100.2%	$3.0M+21207.1%	-$14K
Financing Cash Flow	$51.2M+1707.1%	$2.8M	$0+100.0%	-$161K	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MBOT Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-189.7%-60.8pp	-129.0%+9.1pp	-138.1%-70.6pp	-67.5%-32.6pp	-34.9%-15.4pp	-19.5%
Current Ratio	2.37+0.3	2.09-2.2	4.26-3.7	8.00-10.8	18.78+11.3	7.45
Debt-to-Equity	0.71-0.1	0.85+0.5	0.31+0.1	0.17+0.1	0.08-0.1	0.18
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-4.4%+57.4pp	-61.7%	N/A	-27.5%	N/A	-46.8%	N/A	-13.0%
Current Ratio	27.53+25.2	2.37+0.3	2.09-3.5	5.64+1.4	4.26+0.3	4.00-4.0	8.00-5.5	13.47
Debt-to-Equity	0.05-0.7	0.71-0.1	0.85+0.6	0.21-0.1	0.31-0.0	0.34+0.2	0.17+0.1	0.10
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

ANTERIS TECHNOLOGIES GLOBAL AVR

$545.3M

$216.3M

$194.1M

$154.6M

$193.2M

Frequently Asked Questions

Is Microbot Med Inc profitable?

No, Microbot Med Inc (MBOT) reported a net income of -$11.4M in fiscal year 2024.

What is Microbot Med Inc's earnings per share (EPS)?

Microbot Med Inc (MBOT) reported diluted earnings per share of $-0.73 for fiscal year 2024. This represents a 30.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Microbot Med Inc's EBITDA?

Microbot Med Inc (MBOT) had EBITDA of -$11.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Microbot Med Inc's free cash flow?

Microbot Med Inc (MBOT) generated -$8.9M in free cash flow during fiscal year 2024. This represents a -3.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Microbot Med Inc's operating cash flow?

Microbot Med Inc (MBOT) generated -$8.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Microbot Med Inc's total assets?

Microbot Med Inc (MBOT) had $6.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Microbot Med Inc's capital expenditures?

Microbot Med Inc (MBOT) invested $25K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Microbot Med Inc spend on research and development?

Microbot Med Inc (MBOT) invested $6.6M in research and development during fiscal year 2024.

How many shares does Microbot Med Inc have outstanding?

Microbot Med Inc (MBOT) had 19M shares outstanding as of fiscal year 2024.

What is Microbot Med Inc's current ratio?

Microbot Med Inc (MBOT) had a current ratio of 2.37 as of fiscal year 2024, which is generally considered healthy.

What is Microbot Med Inc's debt-to-equity ratio?

Microbot Med Inc (MBOT) had a debt-to-equity ratio of 0.71 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Microbot Med Inc's return on assets (ROA)?

Microbot Med Inc (MBOT) had a return on assets of -189.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Microbot Med Inc's cash runway?

Based on fiscal year 2024 data, Microbot Med Inc (MBOT) had $3.1M in cash against an annual operating cash burn of $8.8M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Microbot Med Inc's Piotroski F-Score?

Microbot Med Inc (MBOT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Microbot Med Inc's earnings high quality?

Microbot Med Inc (MBOT) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.